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Abstract 
 
Aims. Protein kinases are potential therapeutic targets for heart failure, but most studies of 
cardiac protein kinases derive from other systems, an approach that fails to account for 
specific kinases expressed in the heart and the contractile cardiomyocytes.  We aimed to 
define the cardiomyocyte kinome (i.e. the protein kinases expressed in cardiomyocytes) and 
identify kinases with altered expression in human failing hearts.  Methods and Results. 
Expression profiling (Affymetrix microarrays) detected >400 protein kinase mRNAs in rat 
neonatal ventricular myocytes (NVMs) and/or adult ventricular myocytes (AVMs), 32 and 93 
of which were significantly upregulated or downregulated (>2-fold), respectively, in AVMs.  
Data for AGC family members were validated by qPCR.  Proteomics analysis identified >180 
cardiomyocyte protein kinases, with high relative expression of mitogen-activated protein 
kinase cascades and other known cardiomyocyte kinases (e.g. CAMKs, cAMP-dependent 
protein kinase).  Other kinases are poorly-investigated (e.g. Slk, Stk24, Oxsr1).  Expression 
of Akt1/2/3, BRaf, ERK1/2, Map2k1, Map3k8, Map4k4, MST1/3, p38-MAPK, PKCδ, Pkn2, 
Ripk1/2, Tnni3k and Zak was confirmed by immunoblotting.  Relative to total protein, 
Map3k8 and Tnni3k were upregulated in AVMs vs NVMs.  Microarray data for human hearts 
demonstrated variation in kinome expression that may influence responses to kinase 
inhibitor therapies.  Furthermore, some kinases were upregulated (e.g. NRK, JAK2, STK38L) 
or downregulated (e.g. MAP2K1, IRAK1, STK40) in human failing hearts.  Conclusions.  
This characterization of the spectrum of kinases expressed in cardiomyocytes and the heart 
(cardiomyocyte and cardiac kinomes) identified novel kinases, some of which are 
differentially expressed in failing human hearts and could serve as potential therapeutic 
targets. 
 
Key words:  protein kinases, heart, cardiac myocytes, postnatal development, human heart 
failure 
 
Abbreviations: AMPK, AMP-activated protein kinase; AVMs, adult ventricular myocytes; 
BSA, bovine serum albumin; CAMK, calcium/calmodulin-dependent protein kinase; DCM, 
dialted cardiomyopathy; ERK, extracellular signal-regulated kinase; GST, glutathione S-
transferase; HF, heart failure; IHF, ischaemic heart failure; JNK, c-Jun N-terminal kinase; 
MAPK, mitogen-activated protein kinase; MKK, MAPK kinase; MS, mass spectrometry; 
NVMs, neonatal ventricular myocytes; PKC, protein kinase C. 
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1.  Introduction 
 
Protein kinases regulate many aspects of cell function and represent one of the largest 
supergene families.  The kinome concept was crystallised in 2002 with the report of the 
human kinome (the full protein kinase complement of the genome),1 followed by the mouse 
kinome.2  There are >500 potential protein kinases in the mammalian genome classified into 
8 superfamilies (AGC, Atypical, CAMK, CK1, CMGC, STE, TK, TKL) according to homology 
within their catalytic domains.  Additional kinases (classified as "other") have greater 
variability.  Some kinome members are pseudokinases lacking one or more critical features 
required for a fully active enzyme, but these are increasingly recognised as important 
regulators of protein kinase signalling.3 
 Protein kinases are potential therapeutic targets for heart failure (HF).4-8  However,  
protein kinase regulation and function are usually studied in proliferating cells in relation to 
cancer for which they are attractive therapeutic targets.9  This is delivering an increasing 
range of protein kinase inhibitors as cancer therapies, but kinases that promote cancer are 
often required for cardiac function and at least some of these kinase inhibitors have 
cardiotoxic effects in a significant percentage of patients.10-12  The emphasis on protein 
kinases in non-cardiac, cancerous cells also overlooks selective expression and specific 
roles of protein kinases in the heart, particularly in the highly-specialised contractile 
cardiomyocytes. 
 Mammalian cardiomyocytes withdraw from the cell cycle in the perinatal period.  
Postnatally, as the animal grows, terminally-differentiated cardiomyocytes enlarge and 
increase their contractile apparatus, a process associated with changes in gene 
expression.13  Adult cardiomyocytes hypertrophy (increase in size without cell division) in 
response to an increased workload.  This may be beneficial and reversible (as in pregnancy 
or endurance exercise) but, in pathological conditions (e.g. hypertension or following 
myocardial infarction in which surviving cardiomyocytes hypertrophy to maintain cardiac 
output in the face of cardiomyocyte loss) it may become deleterious and lead to HF.  Protein 
kinase signalling plays a significant role in regulating these events,5-7 but the relative 
importance of individual kinases is not clear and many highly-expressed cardiomyocyte 
kinases remain unstudied in this context.  Here, we addressed the question of which protein 
kinases are expressed in cardiomyocytes.  We assessed the changes during postnatal 
development, comparing profiles in rat neonatal ventricular cardiomyocytes (NVMs) with 
adult ventricular cardiomyocytes (AVMs).  We also examined RNA expression profiles of 
human myocardial biopsies, identifying changes in kinase mRNA expression associated with 
HF.   
 
2.  Methods 
 
2.1  Cardiomyocyte and neonatal non-cardiomyocyte preparation 
Sprague-Dawley female rats with 2 day litters (Harlan SeraLab Ltd. UK) were housed in the 
Imperial College Central Biomedical Services or the University of Reading facility with water 
and food ad libitum.  The facilities are UK registered with Home Office certificates of 
designation.  All procedures in these facilities were performed in accordance with UK 
regulations.  Sprague-Dawley male rats (300-350 g) were from Harlan SeraLab Ltd. UK or 
Charles River Laboratories Canada Inc. and were housed in the University of Reading or 
Montreal Heart Institute facility with water and food ad libitum.  Work with adult male rats 
was undertaken in accordance with local institutional animal care committee procedures and 
either the U.K. Animals (Scientific Procedures) Act 1986 or the Canadian Council on Animal 
Care.  Rat NVMs and non-myocytes were prepared and cultured from Sprague-Dawley rats 
as previously described14 and detailed in the Supplemental Methods.  Rat AVMs were 
prepared from male Sprague Dawley rats (300-350 g) as previously described.15,16  AVMs 
were collected under gravity to give negligible contamination with non-myocytes, then 
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washed in warmed PBS (37°C, 3 × 5 ml) with collection by centrifugation (5 min, 60×g, 
20°C).  Further details are in the Supplemental Methods. 
 
2.2  RNA preparation, microarray analysis and qPCR 
Total RNA was prepared from NVMs and AVMs as described in the Supplemental Methods.  
cRNA was prepared as previously described.14  Fragmentation of antisense cRNA and 
hybridization to Affymetrix rat genome 230 2.0 arrays was performed at the CSC/IC 
Microarray Centre (Imperial College London) according to the manufacturer's instructions.  
Data were exported to ArrayExpress (ArrayExpress ID: E-MTAB-2832).  qPCR was 
performed as described in the Supplemental Methods with specific primers (Supplemental 
Table 1).  Values for selected mRNAs were normalized to Gapdh expression.  Samples for 
microarray analysis were prepared from 3 independent cardiomyocyte preparations.  
Samples for qPCR were from at least 3 independent cardiomyocyte preparations and were 
not those used for microarray analysis. 
 Microarray data (.CEL files) were analysed using GeneSpring (Agilent Technologies) 
12.6.1 (cardiomyocytes) or 13 (human microarray data), using the PLIER16 algorithm with 
normalisation per gene to the gene median.  To identify changes in kinase mRNA 
expression in human failing hearts, datasets were downloaded from ArrayExpress (E-
GEOD-57338,17 E-GEOD-29819,18 E-GEOD-26887,19 E-GEOD-21610,20 E-GEOD 1145, E-
GEOD-540621).  The numbers of patients studied are provided in Supplemental Table 2.  Full 
details of microarray data analysis are provided in the Supplemental Methods. 
 
2.3  Analysis of the kinase proteome 
NVMs and AVMs were prepared as described in the Supplemental Methods.  Two 
independent cardiomyocyte samples (NVM samples were prepared from 15 rat hearts for 
each preparation; AVM samples were from a single heart each) were shipped to KiNative™ 
for kinase profiling as described in 22,23 and described in full in the Supplemental Methods.   
 
2.4  Western blotting 
Recombinant human MKK1 (MAP2K1) and p38-MAPKα (MAPK14) were expressed as 
glutathione S-transferase (GST) fusion proteins and prepared as previously described.24-26  
Other recombinant human GST-fusion proteins were obtained commercially (AKT1, R & D 
Systems, 1775-KS-010; RIPK1, Abnova, H00008737-P01; PKN2 Life Technologies Ltd., 
PV3879).  Concentrations of recombinant proteins were determined relative to BSA 
standards on Coomassie Brilliant Blue-stained gels.  Cardiomyocyte samples were prepared 
and immunoblotting performed as previously described,14 with additional details in the 
Supplemental Methods.  Details of antibodies are in Supplemental Table 3.  Samples for 
immunoblotting were from at least 3 independent cardiomyocyte preparations and were not 
those used for proteomics. 
 
2.5  Immunostaining 
NVMs were immunostained for troponin T as described in 14 and myofilamentous actin was 
counterstained with Texas Red®-X phalloidin as described in 27.  Full details are provided in 
the Supplemental Methods.  Coverslips were mounted using fluorescence mounting medium 
(Dako) and viewed with a Zeiss Axioskop fluorescence microscope using a 40× objective. 
Digital images captured using a Canon PowerShot G3 camera were reduced in size and 
superimposed using Adobe Photoshop 7.0.  
 
3.  Results 
 
3.1  mRNA expression profiling of protein kinases and pseudokinases in neonatal and 
adult rat cardiomyocytes 
mRNA expression profiles for Sprague-Dawley rat NVMs (2-4 d, as cardiomyocytes exit the 
cell cycle28) and AVMs were compared using Affymetrix rat genome 230 2.0 microarrays.  
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Hierarchical clustering of samples segregated AVMs from NVMs (Supplemental Figure 1A) 
with differential expression (>2-fold, false discovery rate p<0.05) of 4720 mRNAs 
(Supplemental Spreadsheet 1).  As expected,28 expression of cell cycle genes declined in 
AVMs relative to NVMs, together with Orc2-6  and Mcm2-7, genes critical for DNA 
replication (Supplemental Figure 1, B and C).  We also detected the expected isoform 
switching of mRNAs for α- and β-myosin heavy chains and thin filament proteins, with 
downregulation of atrial natriuretic factor (Supplemental Figure 1D).29,30  NVM cultures 
inevitably contain some non-myocytes.  By immunostaining cardiomyocytes for troponin T 
and counterstaining all cells with phalloidin, we estimated the number of non-myocytes as 
~5% (Supplemental Figure 2, A-F).  Orc1-6 mRNAs were significantly lower in NVMs 
compared with neonatal cardiac non-myocytes, whilst non-myocytes had negligible 
expression of myocyte-specific genes (Supplemental Figure 2, G and H).  Because RNA 
was prepared from freshly isolated AVMs collected under gravity, these cells have negligible 
non-cardiomyocyte content. Thus, the microarray gene expression profiles are essentially 
those of cardiomyocytes. 
 We identified microarray probesets for 438 protein kinases, 408 of which were 
detected in NVMs and/or AVMs (Figure 1A; Supplemental Spreadsheet 2).  Thirty-two and 
93 were upregulated or downregulated (>2-fold; p<0.05), respectively, in AVMs relative to 
NVMs, and these were distributed between protein kinase families (Figure 1, B and C).  
Some changes (Figure 2, A and B) were expected (e.g. upregulation of Pdk1/2/431 and 
downregulation of Cdk1/428 in AVMs) or predicted (e.g. upregulation of Ttn in AVMs).  
However, other kinases substantially upregulated in AVMs have not been well-studied in 
cardiomyocytes (e.g. Adck3, Hipk2).  We selected 20 AGC kinases for validation by qPCR.  
mRNA expression ratios for AVMs:NVMs for the two methods were within 2-fold for 15 
kinases (Figure 2C).  Both methods confirmed downregulation in AVMs vs NVMs for protein 
kinase C δ (PKCδ; Prkcd) and Cdc42bpb, although qPCR revealed a greater degree of 
downregulation.  The data for PKCδ are consistent with previous work showing that the 
protein is downregulated in AVMs.32  Mast3 was the only anomaly with an AVM:NVM ratio of 
1.0 using microarrays and 0.25 with qPCR.  This may reflect the 5% analysis error, or result 
from expression of alternatively-spliced transcripts, since many kinases (including MAST3 in 
humans) are alternatively spliced.33  To confirm that the detection threshold was appropriate, 
we compared Ct values.  Consistent with microarray data, Ct values for Sgk1, Mast2, Mast3 
and Mast4 (21.8-25.0) were substantially lower than Sgk2 and Mast1 (33.0; considered 
undetectable) (Figure 2D).   
 
3.2  Protein expression of cardiomyocyte protein kinases 
There are several global proteomics studies of rodent and human hearts from which data for 
expressed protein kinases can be mined (e.g. 34-38).  However, cardiomyocytes constitute 
~70% of heart volume, but only ~30% the cell number.39  To identify highly expressed 
cardiomyocyte kinases, we used ActivX ATP probes for affinity purification of protein kinases 
in cardiomyocytes prior to identification/quantification by mass-spectrometry (MS) using 
KiNativ™.40  This affinity purification approach concentrates ATP-binding proteins, 
simplifying the MS spectra for analysis and facilitating protein kinase identification.  
Nevertheless, the spectra remain complex and 321 protein and lipid kinases were targeted 
for identification (Supplemental Spreadsheet 3; Supplemental Tables 4-7).  We detected 
over 180 protein kinases [some isoforms (e.g. JNK1/2/3) could not be distinguished because 
discriminating peptide sequences were not obtained] and 12 lipid kinases in cardiomyocytes 
(Supplemental Spreadsheet 3). 
 The most highly represented pathway was the extracellular signal-regulated kinase 
(ERK) 1/2 cascade (Figure 3; Supplemental Spreadsheet 3).  c-Jun N-terminal kinase (JNK) 
and p38-MAPK pathways were also highly-expressed and other established cardiomyocyte 
protein kinases were detected [e.g. calcium/calmodulin-dependent protein kinases 
(CAMKs),41 AMP-activated protein kinase (AMPK)42, cAMP-dependent protein kinase 
(PKA)43].  Downstream components of the Akt pathway44 were detected, but not Akt isoforms 
themselves.  Akt1 was screened for (Supplemental Table 4), but the peptide selected may 
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be phosphorylated,45,46 potentially causing complications.  Several cardiomyocyte protein 
kinases identified are poorly-investigated in the heart including STE20 kinases [Slk, Stk24 
(MST3), Oxsr1], MLK kinases (Zak, Ilk), and others [e.g. BRaf, Stk38/38l (NDR1/2), Cdk5].  
We previously studied MST3 and NDR1/2 proteins in NVMs,47,48 and it is reasonable to 
expect that other kinases should be detectable at the protein level. Indeed, Zak and Map4k4 
were detected in cardiomyocytes by immunoblotting, with Zak being expressed 
predominantly as the smaller isoform (52 kDa cf. 92 kDa)49 and multiple isoforms of 
Map4k450 (Supplemental Figure 3, A and B).  Many kinases detected with microarrays were 
not detected by proteomics.  Some (e.g. PKCα/ε32) are expressed in cardiomyocytes and, for 
these, expression levels are clearly below the level of detection by proteomics.  For kinases 
not detected by proteomics, Supplemental Tables 4 and 5 provide references for proteins 
detected in cardiomyocyte or heart extracts, Supplemental Table 6 provides references for 
mRNAs detected in heart and Supplemental Table 7 lists kinases that remain to be studied 
in cardiomyocytes. 
 Proteomics data were validated by immunoblotting.  Quantitative immunoblotting 
[with glutathione S-transferase (GST) fusion proteins as standards] was used for MKK1/2 (a 
highly represented kinase detected by proteomics), p38-MAPKs (less abundant) and Pkn2 
(low relative levels), in addition to Akt1/2/3 (not detected by proteomics) and Ripk1 (not 
studied by proteomics) (Supplemental Figure 4).  It should be noted that GST increases the 
relative molecular mass and, because smaller proteins are transferred more efficiently, 
concentrations of endogenous proteins may be overestimated.  Furthermore, the antibodies 
used cannot distinguish between MKK1/MKK2, p38-MAPKs and Akt1/Akt2/Akt3.  MKK1/2 
were detected at 9.8- and 6.3-fold higher levels than p38-MAPKs in NVMs and AVMs, 
respectively (~7.0 and ~7.8-fold higher in the proteomics study), with substantially lower 
levels of Pkn2 (Figure 4, A and B).  Akt1/2/3 were detected at similar levels to p38-MAPKs, 
whilst Ripk1 was more highly expressed.  For all, expression was lower in AVMs than NVMs, 
but with a smaller relative decrease for Ripk1 (~2.1-fold). 
 To determine if there is differential expression in cardiomyocytes relative to cardiac 
non-myocytes, we compared selected protein kinases in neonatal or adult rat hearts with 
NVMs or AVMs, respectively.  In neonates, MKK1/2, Akt1/2/3, ERK1/2, MST1 and Pkn2 
expression was similar in hearts or NVMs, whilst p38-MAPKs and MST3 were more highly 
expressed in hearts, and Ripk1 and Pkn2 were enriched in NVMs (Figure 4C, Supplemental 
Figure 5).  In adults, Ripk1 was similarly expressed in AVMs and adult hearts, and Pkn2 
remained enriched in AVMs, but other kinases were expressed at higher levels in whole 
hearts (Figure 4D, Supplemental Figure 5).  Thus, relative levels of expression of different 
protein kinases in cardiomyocytes and non-myocytes vary during postnatal development 
with some protein kinases (e.g. Pkn2) remaining more highly enriched in cardiomyocytes.   
 The proteomics data cannot compare levels of expression in NVMs with AVMs on a 
per cell basis because of the increase in size during postnatal development (membrane 
capacitance, an index of cell size, increases from 13 pF in 1-2 d NVMs to 156 pF in 
AVMs51,52) with increased expression of, for example, contractile proteins.  Nevertheless, two 
kinases, Map3k8 and Tnni3k, were considerably more highly expressed in AVMs than NVMs 
(Supplemental Figure 3C) and such kinases are likely to play a particularly important role in 
the adult state.  Most protein kinases were more highly expressed in NVMs (Akt1/2/3, BRaf, 
ERK1/2, MAP4K4, MKK1/2, MST1, MST3, p38-MAPK, PKCδ, Pkn2, Ripk1, Ripk2, Zak; 
Supplemental Figure 3D).  However, because of the increase in cell size, at least some are 
probably expressed at similar or higher levels in AVMs on a per cell basis (as for PKCα and 
PKCε32).   
 
3.3  Protein kinase mRNAs in human failing hearts 
To explore variability of protein kinase expression in human hearts and determine whether 
expression profiles change in heart failure (HF), we mined Affymetrix microarray data from 
the ArrayExpress database (Supplemental Table 2).  Initially, we used E-GEOD-57338 with 
data for samples from non-failing (NF) male (n=63) and female (n=73) left ventricles,17 and 
detected 402 protein kinase mRNAs (Supplemental Spreadsheet 4).  Only ADCK3 was 
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differentially expressed in male vs female hearts (>1.2-fold; p<0.05).  There was variation in 
expression between patients, although some protein kinase mRNAs showed much greater 
variation than others (Figure 5).  We compared data for male NF samples with samples from 
male patients with dilated cardiomyopathy (DCM; n=63) or ischaemic heart failure (IHF; 
n=81), and female NF samples with samples from female patients with DCM (n=19) or IHF 
(n=14) (i.e. 4 groups), identifying kinases that were significantly different in the failing hearts 
(>1.25-fold, p<0.05).  Candidate HF kinases were selected if significantly changed in 3 (15 
kinases) or 4 (16 kinases) of these groups (Supplemental Spreadsheet 5).  We then 
interrogated other, smaller datasets for expression of these kinases (Supplemental 
Spreadsheets 6-10).  Of the candidate HF kinases, mRNAs for NRK (but not the related 
kinase MAP4K4), JAK2 (but not JAK1), EPHA3, STK38L and KIT were significantly 
upregulated in HF samples relative to NF controls in all datasets studied, regardless of 
aetiology, with upregulation of NTRK2, ADRBK2 and MAPK10 in all but one of the datasets 
(Figure 6).  Furthermore, mRNAs for MAP2K1 and IRAK1 (but not related kinases MAP2K2 
or IRAK4) were downregulated in all HF samples relative to NF controls, with downregulation 
of MAP2K3, MAP3K3, TESK1, PIM1 and STK40 in at least 3 of the additional 5 datasets 
studied (Figure 7).  It remains to be established whether the changes contribute to or are a 
consequence of the HF phenotype. 
  
4.  Discussion 
 
As enzymes with substrate binding sites and active sites for catalysis, protein kinases are 
ideal targets for small molecule therapies, features being exploited in cancer therapeutics.  
Protein kinases play an important role in the development of heart failure, and many key 
protein kinases in heart and in cardiomyocytes have been studied, with much emphasis on 
their potential as therapeutic targets.4-8  However, there has not been a systematic analysis 
of protein kinases that regulate cardiomyocyte and cardiac function.  To start to address this, 
we present here the first global analysis of the rat cardiomyocyte kinome and human cardiac 
kinome. 
 Our first approach used microarrays for mRNA expression profiling of rat 
cardiomyocytes.  We identified 408 protein kinases with detectable expression in NVMs 
and/or AVMs, most of which did not change substantially during postnatal development 
(Figure 1; Supplemental Spreadsheet 2).  This is a higher proportion of the total kinome than 
might be anticipated but, given the general importance of protein kinases in cellular 
functions, perhaps not entirely unexpected.  The relative levels of expression of the kinases 
is important and, whilst we can gauge whether or not a kinase is likely to be expressed at 
high or low levels from microarray data (e.g. Ttn, Pink1 and Mylk3, with raw fluorescence 
values >1000 in AVMs, are probably highly expressed compared with Akt3 and Cdk1, with 
raw fluorescence values ~100), protein expression levels are more relevant than transcript 
levels.   
 mRNA expression profiling remains far more sensitive than global proteomics 
profiling approaches.  One reason is that global proteomics systems favour detection of 
abundant proteins, and protein kinases (as regulatory enzymes rather than functional 
components of, for example, the cytoskeleton or mitochondria) are not necessarily abundant.  
Thus, even when the system is simplified by analysis of subcellular fractions or individual 
organelles (as in 37,38), previous studies of heart samples reported only limited numbers of 
protein kinases (see, for example, 34-38).  There are fewer proteomics studies of protein 
kinases in cardiomyocytes and these are usually highly focused.  For example, proteomics 
has been used to study the PKCε interactome, identifying 12 kinases.53  With >400 kinases 
detected at the mRNA level, we needed a different approach to confirm protein expression of 
as many kinases as possible.  To increase the profiling capability for protein kinases at the 
protein level, we used ActivX ATP probes for affinity purification of protein kinases in AVMs 
and NVMs prior to identification and quantification by MS.  As with any technique, this 
system is not perfect and, although >400 protein and lipid kinases can be identified, not all 
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are detected in the screen including some (Ttn and Pink1) that are highly expressed at the 
mRNA level in cardiomyocytes (Figure 2A; Supplemental Spreadsheet 2).  Additionally, 
because of the complexity of the MS data, it was also still necessary to limit the screen to 
321 kinases.  Nevertheless, we detected over 180 protein kinases in NVMs and/or AVMs, 
some of which have not been studied previously in relation to cardiac disorders.   
 For the kinases detected by proteomics, we could clearly establish that they are 
expressed as proteins and gain some insight into the relative levels of expression.  We 
validated our proteomics data by immunoblotting and extended the data to some kinases 
that were not studied using proteomics (Akt, Ripk1).  Immunoblotting also has limitations, 
most particularly in the availability of specific and sensitive antibodies.  For this study, we 
screened a number of different antibodies to different kinases, many of which could not be 
used because of a lack of specificity and/or insufficient sensitivity.  However, subject to 
antibody availability, immunoblotting is undoubtedly very powerful for studies of individual 
protein kinases, allowing comparison in different cells (e.g. AVMs vs NVMs), tissues (e.g. 
cardiomyocytes vs whole hearts) and, though not undertaken here, subcellular 
compartmentalisation.  Further information can be gained relating to isoform expression as 
with Zak and Map4k4 (Supplemental Figure 3), although sometimes antibodies cannot 
distinguish between isoforms (e.g. Akt1/2/3).  For the remaining kinases that were studied 
but not detected by proteomics, this could be because expression was below the level of 
detection.  For some, this is clearly the case given that they have been detected and studied 
in cardiomyocytes previously (Supplemental Table 4).  Some have been detected in heart 
extracts (Supplemental Table 5), whilst others remain to be investigated at the protein level 
(Supplemental Tables 6 and 7).  For the remaining kinases not studied by proteomics, 
further studies are clearly required although many have already been shown to be 
expressed in cardiomyocytes and/or heart and have been actively investigated 
(Supplemental Tables 4 and 5).   
 Our cardiomyocyte kinome data highlight protein kinases that are expressed and 
may be therapeutic targets for cardiac disorders and other diseases.  From the cancer 
therapies already in clinical use, there is clear variation in the cardiac responsiveness to 
protein kinase inhibitors with, for example, cardiac dysfunction in up to 9.4% of patients 
treated with Herceptin10,11 and ~7% of patients treated with the MKK1/2 inhibitor trametinib.12  
Our data demonstrate differential expression of the cardiac kinome between patients (Figure 
5; Supplemental Spreadsheet 4) that may influence the degree to which they respond to 
therapeutic administration of kinase inhibitors.  The human cardiac kinome data also provide 
an indication of potential changes in protein kinase expression in failing hearts (Figures 6 
and 7;  Supplemental Spreadsheets 5-10).  The approach we used was facilitated by 
publication of microarray data from a large cohort of 313 patients (E-GEOD-5733817) giving 
us the opportunity to compare male and female hearts, in addition to NF and failing hearts.  
None of the other datasets available had sufficient numbers, particularly of NF samples, to 
initiate the study.  Furthermore, in several cases, NF samples were biased towards females 
whilst the HF samples were biased towards males.  With E-GEOD-57338, we could identify 
changes common to male vs female DCM and IHF.  E-GEOD-57338 also allowed us to 
establish that there was little difference in protein kinase mRNA expression between males 
and females, allowing us to interrogate the other datasets.  The consistency of many of the 
changes between 5 different datasets from different investigators using patient cohorts with 
different aetiologies was highly notable, strongly suggesting that the changes we identified 
are common features of HF.  Clearly, the changes in mRNA expression remain to be 
validated at the protein level, whether the changes are cause or consequence remains to be 
determined and the effects of the changes remains to be established. 
 In summary, we present the first study of the rat cardiomyocyte and human cardiac 
kinomes.  The data highlight the importance of many well-characterised protein kinase 
pathways in the heart, and establish the potential importance of novel kinases for further 
study.  The latter represent potential novel, therapeutic targets for HF.  Understanding their 
input into the cardiomyocyte signalling network and their role in cardiomyocyte function will 
also be essential for "fine-tuning" current therapeutic approaches for HF.   
CVR-2014-1342R2 
 
9 
 
 
Funding 
This work was supported by grants from Heart Research UK (TRP02/13), the British Heart 
Foundation (FS/11/7/28642, FS/13/64/30439, PG/03/014/15059, PG/13/71/30460) and the 
Heart and Stroke Foundation of Canada. 
 
Acknowledgement 
We wish to thank Dr. Timothy J. Kemp for preparation of RNA samples for microarray 
analysis. 
 
Conflict of interest: none declared. 
 
 
References 
 
1.  Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase 
complement of the human genome. Science 2002;298:1912-1934. 
2.  Caenepeel S, Charydczak G, Sudarsanam S, Hunter T, Manning G. The mouse kinome: 
discovery and comparative genomics of all mouse protein kinases. Proc Natl Acad Sci U S A 
2004;101:11707-11712. 
3.  Reiterer V, Eyers PA, Farhan H. Day of the dead: pseudokinases and 
pseudophosphatases in physiology and disease. Trends Cell Biol 2014;24:489-505. 
4.  Vlahos CJ, McDowell SA, Clerk A. Kinases as therapeutic targets for heart failure. Nat 
Rev Drug Discov 2003;2:99-113. 
5.  Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling 
pathways. Nat Rev Mol Cell Biol 2006;7:589-600. 
6.  Clerk A, Cullingford TE, Fuller SJ, Giraldo A, Markou T, Pikkarainen S, Sugden PH. 
Signaling pathways mediating cardiac myocyte gene expression in physiological and stress 
responses. J Cell Physiol 2007;212:311-322. 
7.  Maillet M, van Berlo JH, Molkentin JD. Molecular basis of physiological heart growth: 
fundamental concepts and new players. Nat Rev Mol Cell Biol 2013;14:38-48. 
8.  Tarone G, Balligand JL, Bauersachs J, Clerk A, De WL, Heymans S, Hilfiker-Kleiner D, 
Hirsch E, Iaccarino G, Knoll R, Leite-Moreira AF, Lourenco AP, Mayr M, Thum T, Tocchetti 
CG. Targeting myocardial remodelling to develop novel therapies for heart failure: A position 
paper from the Working Group on Myocardial Function of the European Society of 
Cardiology. Eur J Heart Fail 2014;16:494-508. 
9.  Knapp S, Sundstrom M. Recently targeted kinases and their inhibitors-the path to clinical 
trials. Curr Opin Pharmacol 2014;17C:58-63. 
10.  Fuller SJ, Sivarajah K, Sugden PH. ErbB receptors, their ligands, and the consequences 
of their activation and inhibition in the myocardium. J Mol Cell Cardiol 2008;44:831-854. 
11.  de Azambuja E., Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, 
Steinseifer J, Untch M, Smith IE, Gianni L, Baselga J, Jackisch C, Cameron DA, Bell R, 
Leyland-Jones B, Dowsett M, Gelber RD, Piccart-Gebhart MJ, Suter TM. Trastuzumab-
associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 
1-01). J Clin Oncol 2014;32:2159-2165. 
12.  Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, 
Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, III, Falchook G, Algazi A, Lewis 
K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, 
Patel K, Weber J. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 
Mutations. N Engl J Med 2012;367:1694-1703. 
13.  Dorn GW, II, Robbins J, Sugden PH. Phenotyping hypertrophy: eschew obfuscation. 
Circ Res 2003;92:1171-1175. 
14.  Marshall AK, Barrett OP, Cullingford TE, Shanmugasundram A, Sugden PH, Clerk A. 
ERK1/2 signaling dominates over RhoA signaling in regulating early changes in RNA 
CVR-2014-1342R2 
 
10 
 
expression induced by endothelin-1 in neonatal rat cardiomyocytes. PLoS One 
2010;5:e10027. 
15.  Fuller SJ, Sugden PH. Protein synthesis in rat cardiac myocytes is stimulated at the 
level of translation by phorbol esters. FEBS Lett 1989;247:209-212. 
16.  Chevalier D, Allen BG. Two distinct forms of MAPKAP kinase-2 in adult cardiac 
ventricular myocytes. Biochemistry 2000;39:6145-6156. 
17.  Liu Y, Morley M, Brandimarto J, Hannenhalli S, Hu Y, Ashley EA, Tang WH, Moravec 
CS, Margulies KB, Cappola TP, Li M. RNA-Seq identifies novel myocardial gene expression 
signatures of heart failure. Genomics 2015;105:83-89. 
18.  Gaertner A, Schwientek P, Ellinghaus P, Summer H, Golz S, Kassner A, Schulz U, 
Gummert J, Milting H. Myocardial transcriptome analysis of human arrhythmogenic right 
ventricular cardiomyopathy. Physiol Genomics 2012;44:99-109. 
19.  Greco S, Fasanaro P, Castelvecchio S, D'Alessandra Y, Arcelli D, Di DM, Malavazos A, 
Capogrossi MC, Menicanti L, Martelli F. MicroRNA dysregulation in diabetic ischemic heart 
failure patients. Diabetes 2012;61:1633-1641. 
20.  Schwientek P, Ellinghaus P, Steppan S, D'Urso D, Seewald M, Kassner A, Cebulla R, 
Schulte-Eistrup S, Morshuis M, Rofe D, El BA, Korfer R, Milting H. Global gene expression 
analysis in nonfailing and failing myocardium pre- and postpulsatile and nonpulsatile 
ventricular assist device support. Physiol Genomics 2010;42:397-405. 
21.  Hannenhalli S, Putt ME, Gilmore JM, Wang J, Parmacek MS, Epstein JA, Morrisey EE, 
Margulies KB, Cappola TP. Transcriptional genomics associates FOX transcription factors 
with human heart failure. Circulation 2006;114:1269-1276. 
22.  Patricelli MP, Nomanbhoy TK, Wu J, Brown H, Zhou D, Zhang J, Jagannathan S, Aban 
A, Okerberg E, Herring C, Nordin B, Weissig H, Yang Q, Lee JD, Gray NS, Kozarich JW. In 
situ kinase profiling reveals functionally relevant properties of native kinases. Chem Biol 
2011;18:699-710. 
23.  Patricelli MP, Szardenings AK, Liyanage M, Nomanbhoy TK, Wu M, Weissig H, Aban A, 
Chun D, Tanner S, Kozarich JW. Functional interrogation of the kinome using nucleotide 
acyl phosphates. Biochemistry 2007;46:350-358. 
24.  Bogoyevitch MA, Marshall CJ, Sugden PH. Hypertrophic agonists stimulate the activities 
of the protein kinases c-Raf and A-Raf in cultured ventricular myocytes. J Biol Chem 
1995;270:26303-26310. 
25.  Alessi DR, Saito Y, Campbell DG, Cohen P, Sithanandam G, Rapp U, Ashworth A, 
Marshall CJ, Cowley S. Identification of the sites in MAP kinase kinase-1 phosphorylated by 
p74raf-1. EMBO J 1994;13:1610-1619. 
26.  Stokoe D, Campbell DG, Nakielny S, Hidaka H, Leevers SJ, Marshall C, Cohen P. 
MAPKAP kinase-2; a novel protein kinase activated by mitogen- activated protein kinase. 
EMBO J 1992;11:3985-3994. 
27.  Sugden PH, Markou T, Fuller SJ, Tham EL, Molkentin JD, Paterson HF, Clerk A. 
Monophosphothreonyl extracellular signal-regulated kinases 1 and 2 (ERK1/2) are formed 
endogenously in intact cardiac myocytes and are enzymically active. Cell Signal 
2011;23:468-477. 
28.  Ahuja P, Sdek P, MacLellan WR. Cardiac myocyte cell cycle control in development, 
disease, and regeneration. Physiol Rev 2007;87:521-544. 
29.  Lompré AM, Nadal-Ginard B, Mahdavi V. Expression of the cardiac ventricular alpha- 
and beta-myosin heavy chain genes is developmentally and hormonally regulated. J Biol 
Chem 1984;259:6437-6446. 
30.  Marston SB, Redwood CS. Modulation of thin filament activation by breakdown or 
isoform switching of thin filament proteins.  Physiological and pathological implications. Circ 
Res 2003;93:1170-1178. 
31.  Sugden MC, Langdown ML, Harris RA, Holness MJ. Expression and regulation of 
pyruvate dehydrogenase kinase isoforms in the developing rat heart and in adulthood: role 
of thyroid hormone status and lipid supply. Biochem J 2000;352:731-738. 
32.  Clerk A, Bogoyevitch MA, Fuller SJ, Lazou A, Parker PJ, Sugden PH. Expression of 
protein kinase C isoforms during cardiac ventricular development. Am J Physiol 
CVR-2014-1342R2 
 
11 
 
1995;269:H1087-H1097. 
33.  Anamika K, Garnier N, Srinivasan N. Functional diversity of human protein kinase splice 
variants marks significant expansion of human kinome. BMC Genomics 2009;10:622. 
34.  Aye TT, Scholten A, Taouatas N, Varro A, Van Veen TA, Vos MA, Heck AJ. Proteome-
wide protein concentrations in the human heart. Mol Biosyst 2010;6:1917-1927. 
35.  Lundby A, Andersen MN, Steffensen AB, Horn H, Kelstrup CD, Francavilla C, Jensen 
LJ, Schmitt N, Thomsen MB, Olsen JV. In vivo phosphoproteomics analysis reveals the 
cardiac targets of β-adrenergic receptor signaling. Sci Signal 2013;6:rs11. 
36.  Fernandez-Sanz C, Ruiz-Meana M, Miro-Casas E, Nunez E, Castellano J, Loureiro M, 
Barba I, Poncelas M, Rodriguez-Sinovas A, Vazquez J, Garcia-Dorado D. Defective 
sarcoplasmic reticulum-mitochondria calcium exchange in aged mouse myocardium. Cell 
Death Dis 2014;5:e1573. 
37.  Kislinger T, Cox B, Kannan A, Chung C, Hu P, Ignatchenko A, Scott MS, Gramolini AO, 
Morris Q, Hallett MT, Rossant J, Hughes TR, Frey B, Emili A. Global survey of organ and 
organelle protein expression in mouse: combined proteomic and transcriptomic profiling. Cell 
2006;125:173-186. 
38.  Wypijewski KJ, Tinti M, Chen W, Lamont D, Ashford ML, Calaghan SC, Fuller W. 
Identification of caveolar resident proteins in ventricular myocytes using a quantitative 
proteomic approach: dynamic changes in caveolar composition following adrenoceptor 
activation. Mol Cell Proteomics 2015;14:596-608. 
39.  Souders CA, Bowers SL, Baudino TA. Cardiac fibroblast: the renaissance cell. Circ Res 
2009;105:1164-1176. 
40.  Rosenblum JS, Nomanbhoy TK, Kozarich JW. Functional interrogation of kinases and 
other nucleotide-binding proteins. FEBS Lett 2013;587:1870-1877. 
41.  McKinsey TA. Derepression of pathological cardiac genes by members of the CaM 
kinase superfamily. Cardiovasc Res 2007;73:667-677. 
42.  Zaha VG, Young LH. AMP-activated protein kinase regulation and biological actions in 
the heart. Circ Res 2012;111:800-814. 
43.  Steinberg SF, Brunton LL. Compartmentation of G protein-coupled signaling pathways 
in cardiac myocytes. Annu Rev Pharmacol Toxicol 2001;41:751-763. 
44.  Matsui T, Rosenzweig A. Convergent signal transduction pathways controlling 
cardiomyocyte survival and function: the role of PI 3-kinase and Akt. J Mol Cell Cardiol 
2005;38:63-71. 
45.  Mahajan K, Coppola D, Challa S, Fang B, Chen YA, Zhu W, Lopez AS, Koomen J, 
Engelman RW, Rivera C, Muraoka-Cook RS, Cheng JQ, Schonbrunn E, Sebti SM, Earp HS, 
Mahajan NP. Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. 
PLoS One 2010;5:e9646. 
46.  Zhang J, Chen T, Mao Q, Lin J, Jia J, Li S, Xiong W, Lin Y, Liu Z, Liu X, Zhao H, Wang 
G, Zheng D, Qiu S, Ge J. PDGFR-beta-activated ACK1-AKT signaling promotes glioma 
tumorigenesis. Int J Cancer 2015;136:1769-1780. 
47.  Fuller SJ, Pikkarainen S, Tham EL, Cullingford TE, Molkentin JD, Cornils H, Hergovich 
A, Hemmings BA, Clerk A, Sugden PH. Nuclear Dbf2-related protein kinases (NDRs) in 
isolated cardiac myocytes and the myocardium: activation by cellular stresses and by 
phosphoprotein serine-/threonine phosphatase inhibitors. Cell Signal 2008;20:1564-1577. 
48.  Fuller SJ, McGuffin LJ, Marshall AK, Giraldo A, Pikkarainen S, Clerk A, Sugden PH. A 
novel non-canonical mechanism of regulation of MST3 (mammalian Sterile20-related kinase 
3). Biochem J 2012;442:595-610. 
49.  Bloem LJ, Pickard TR, Acton S, Donoghue M, Beavis RC, Knierman MD, Wang X. 
Tissue distribution and functional expression of a cDNA encoding a novel mixed lineage 
kinase. J Mol Cell Cardiol 2001;33:1739-1750. 
50.  Machida N, Umikawa M, Takei K, Sakima N, Myagmar BE, Taira K, Uezato H, Ogawa 
Y, Kariya K. Mitogen-activated protein kinase kinase kinase kinase 4 as a putative effector of 
Rap2 to activate the c-Jun N-terminal kinase. J Biol Chem 2004;279:15711-15714. 
51.  Cerbai E, Pino R, Sartiani L, Mugelli A. Influence of postnatal-development on I(f) 
occurrence and properties in neonatal rat ventricular myocytes. Cardiovasc Res 
CVR-2014-1342R2 
 
12 
 
1999;42:416-423. 
52.  Banyasz T, Lozinskiy I, Payne CE, Edelmann S, Norton B, Chen B, Chen-Izu Y, Izu LT, 
Balke CW. Transformation of adult rat cardiac myocytes in primary culture. Exp Physiol 
2008;93:370-382. 
53.  Edmondson RD, Vondriska TM, Biederman KJ, Zhang J, Jones RC, Zheng Y, Allen DL, 
Xiu JX, Cardwell EM, Pisano MR, Ping P. Protein kinase C epsilon signaling complexes 
include metabolism- and transcription/translation-related proteins: complimentary separation 
techniques with LC/MS/MS. Mol Cell Proteomics 2002;1:421-433.
CVR-2014-1342R2 
 
13 
 
 
FIGURE LEGENDS 
 
Figure 1.  Expression profiling of protein kinase mRNAs in rat adult ventricular myocytes 
(AVMs) and neonatal ventricular myocytes (NVMs).  mRNA expression profiling for AVMs or 
NVMs (n=3, duplicate hybridisations) used Affymetrix microarrays.  A, Heatmap for relative 
expression of all protein kinases/pseudokinases expressed in AVMs and/or NVMs.  Data 
were normalised to the gene median and are mean values on a log2 scale.  B, Numbers of 
each protein kinase superfamily detected in AVMs and/or NVMs that were similarly 
expressed (within 2-fold; black), more highly expressed in AVMs (blue) or more highly 
expressed in NVMs (green).  C, Differentially expressed protein kinase mRNAs grouped 
according to protein kinase family.  Data were normalised to the gene median and are mean 
values for AVMs (cyan) or NVMs (yellow). 
 
Figure 2.  A and B, Protein kinase mRNAs subject to postnatal developmental regulation in 
cardiomyocytes.  Differentially expressed protein kinase transcripts were identified from the 
microarray data.  Expression ratios are shown for the 30 protein kinases with the highest 
relative level of expression in AVMs (A) or NVMs (B).  C and D, Validation of microarray data 
(solid bars, mean values) using qPCR (open bars, means  SEM, n=3).  Expression ratios 
(AVMs/NVMs) (C) or Ct values (D) are shown.   
 
Figure 3.  Protein expression of cardiomyocyte protein kinases.  Protein kinases in NVMs 
(A) or AVMs (B) were affinity purified, then identified and quantified by mass-spectrometry 
(MS).  Expression of each kinase was calculated as the percentage of the MS signal for that 
kinase relative to the total MS signal for all kinases detected. The area of each circle in the 
diagram is proportional to the percentage value of the kinase relative to the total pool of 
kinases detected.  Data are shown for the principal MAPK cascades, other important 
cardiomyocyte kinases, components of the Akt pathway (pink, although p70S6k and Gsk3 
are also phosphorylated by ERK1/2 and RSKs, respectively) and other kinases within the 30 
most highly represented kinases.  Relatively under-investigated kinases in cardiomyocytes 
are highlighted in dark blue. Common names are in capitals; otherwise gene symbols are 
used. 
 
Figure 4.  Analysis of protein kinase expression by immunoblotting.  A, Quantitative 
immunoblotting of MKK1/2, p38-MAPK, Pkn2, Akt1/2/3 and Ripk1 in NVMs (solid bars) and 
AVMs (open bars) relative to GST fusion protein standards (means ± SEM, n=3).  Primary 
data are in Supplemental Figure 4.  Concentrations are in fmol/µg protein.  B, Proteomics 
data for MKK1/2, p38-MAPK and Pkn2 (mean values, n=2).  C and D, Immunoblot analysis 
comparing expression of selected kinases in neonatal (C) or adult (D) cardiomyocyte and 
whole heart extracts (means ± SEM, n=3/4).  Primary data are in Supplemental Figure 5. 
 
Figure 5.  Protein kinase mRNA expression in non-failing human heart.  Affymetrix Rat 1.1 
ST Gene microarray data (E-GEOD-57338) from male (n=73) or female (n=63) hearts were 
mined for protein kinases.  A, Heatmap showing hierarchical clustering of all detected protein 
kinases and patients.  The bar above indicates male (blue) and female (red) samples.  B-D, 
Detail of the variation of specific kinases.  Data were normalised to the gene median and are 
mean values on a log2 scale.  Heatmaps are from -2 (cyan) through 0 (black) to +2 (red). 
 
Figure 6.  Protein kinase mRNAs upregulated in human heart failure.  Analysis of female 
and male left ventricular samples from E-GEOD-57338 (57338F and 57338M) comparing 
microarray data for non-failing (black bars) with dilated cardiomyopathy (DCM, grey bars) or 
ischaemic heart failure (IHF, white bars) identified candidate protein kinase markers of heart 
failure, with upregulation of NRK (A) not MAP4K4 (B), JAK2 (C) not JAK1 (D), and 
upregulation of EPHA3, (E) NTRK2 (F), STK38L (G), ADRBK2 (H), KIT (I) and MAPK10 (J).  
Other datasets were interrogated for expression of these kinases: E-GEOD-26887 [non-
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diabetic heart failure (grey), diabetic heart failure (white)]; E-GEOD-29819 [DCM (grey), 
arrhythmogenic right ventricular hypertrophy (white)]; E-GEOD-21610, E-GEOD-1145 and E-
GEOD-5406 [DCM (grey), IHF (white)].  NRK and EPHA3 were not represented on the 
microarrays used in E-GEOD-5406. 
 
Figure 7.  Identification of protein kinase mRNAs downregulated in human heart failure.  
Analysis of female and male left ventricular samples from E-GEOD-57338 (57338F and 
57338M) comparing microarray data for non-failing (black bars) with dilated cardiomyopathy 
(DCM, grey bars) or ischaemic heart failure (IHF, white bars) identified candidate protein 
kinase markers of heart failure, with downregulation of MAP2K1 (A) not MAP2K2 (B), IRAK1 
(C) not IRAK4 (D), and downregulation of MAP2K3, (E) RPS6KA2 (F), MAP3K6 (G), TESK1 
(H), PIM1 (I) and STK40 (J).  Other datasets were interrogated for expression of these 
kinases: E-GEOD-26887 [non-diabetic heart failure (grey), diabetic heart failure (white)]; E-
GEOD-29819 [DCM (grey), arrhythmogenic right ventricular hypertrophy (white)]; E-GEOD-
21610, E-GEOD-1145 and E-GEOD-5406 [DCM (grey), IHF (white)].  STK40 was not 
represented on the microarrays used in E-GEOD-5406. 
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Supplemental  Methods 
 
Cardiomyocyte preparation and culture of neonatal non-cardiomyocytes 
 Sprague-Dawley female rats with 2 day litters were purchased from Harlan SeraLab 
Ltd. UK and were housed in the Imperial College Central Biomedical Services or the 
University of Reading facility with water and food ad libitum.  All facilities are UK registered 
with Home Office certificates of designation.  All procedures in these facilities were 
performed in accordance with UK regulations.  Neonatal rats were culled by schedule 1 
(cervical dislocation) for which additional approval and licences are not required according to 
UK regulations.  Adult male Sprague-Dawley rats  were purchased from Harlan SeraLab Ltd. 
UK or Charles River Laboratories Canada Inc. and were housed in the University of Reading 
or Montreal Heart Institute facility with water and food ad libitum.  Work with adult male rats 
was undertaken in accordance with local institutional animal care committee procedures and 
either the U.K. Animals (Scientific Procedures) Act 1986 or the Canadian Council on Animal 
Care. 
 Rat neonatal ventricular myocytes (NVMs) were prepared and cultured from 
Sprague-Dawley rats as previously described.1  Ventricles were dissected from neonatal (1–
2 d) Sprague-Dawley rat hearts and dissociated by serial digestion with 0.4 mg/ml 
collagenase and 0.6 mg/ml pancreatin sterile digestion buffer (116 mM NaCl, 20 mM 
HEPES, 0.8 mM Na2HPO4, 5.6 mM glucose, 5.4 mM KCl and 0.8 mM MgSO4, pH 7.35).  
The first digestion supernatant (5 min, 37°C, 160 cycles/min in a shaking waterbath) was 
removed and discarded.  Cell suspensions from subsequent digestions (4×25 min, 37°C 136 
cycles/min shaking) were recovered by centrifugation (5 min, 60×g) and the cell pellet 
resuspended in plating medium (Dulbecco's modified Eagle's medium (DMEM)/medium 199 
[4:1 (v/v)], 15% (v/v) foetal calf serum (FCS), 100 units/ml penicillin and streptomycin). Cells 
were pre-plated on plastic tissue culture dishes (30 min) to remove non-cardiomyocytes.  
The cells remaining on the pre-plates were cultured in Dulbecco's modified Eagle's medium 
(DMEM)/medium 199 [4:1 (v/v)], 5% (v/v) foetal calf serum (FCS), 100 units/ml penicillin and 
streptomycin until confluent.  They were then trypsinized and divided between two dishes.  
After 24 h, cells were harvested for RNA extraction. 
 For biochemistry and molecular biology experiments, non-adherent viable 
cardiomyocytes were plated at a density of 4×106 cells/dish on 60 mm Primaria dishes pre-
coated with sterile 1% (w/v) gelatin (Sigma-Aldrich UK). After 18 h myocytes were beating 
spontaneously. For immunostaining experiments, cardiomyocytes were plated at 1.5×106 
cells/dish on 35 mm Primaria dishes containing glass coverslips pre-coated with sterile 1% 
(w/v) gelatin followed by laminin (20 µg/ml in PBS; Sigma-Aldrich UK). The plating medium 
was withdrawn and cells were incubated in serum-free maintenance medium 
(DMEM/medium [4:1 (v/v)], 100 units/ml penicillin and streptomycin) for a further 24 h. 
Immunostaining studies indicated that NVM cultures for immunostaining contained up to 
~5% non-myocytes (Supplemental Figure 2). 
 Rat adult ventricular myocytes (AVMs) were prepared from male Sprague Dawley 
rats.  In the UK, all animal experiments were approved by the Imperial College London or 
University of Reading ethics committee and performed according to the the U.K. Animals 
(Scientific Procedures) Act 1986.  Rats (200-250g) were anaesthetised with a lethal 
intraperitoneal dose of Euthatal (pentobarbital sodium, 60 mg/kg).  Once the plane of 
anaesthesia was such that they no longer responded to noxious stimuli (toe pinch), 100 units 
of heparin (1000 units/ml) was administered via the femoral vein.  The chest cavity was 
opened and the heart and lungs were removed into modified ice-cold KHBBS (25 mM 
NaHCO3, 119 mM NaCl, 35 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4 
equilibrated with 95% O2/5% CO2) whilst the heart was still beating.  The surrounding tissues 
were removed from the heart before aortic cannulation.  In Canada, all animal experiments 
were approved by the Montreal Heart Institute ethics committee and performed according to 
the guidelines of the Canadian Council on Animal Care.  Rats (150-180g) were injected 
intraperitoneally with 500 U of heparin and anesthetised with pentobarbital (60 mg/kg). Once 
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the plane of anaesthesia was such that they no longer responded to noxious stimuli (toe 
pinch), rats were decapitated with a with a small animal guillotine (Harvard Apparatus) and 
the hearts rapidly removed, cannulated via the aorta, and subjected to retrograde perfusion. 
Cardiac myocytes were isolated as described previously as previously described.2,3  AVMs 
were collected and initially washed under gravity such that there was negligible 
contamination with non-myocytes, then washed in warmed PBS (37°C, 3 × 5 ml) with 
collection by centrifugation (5 min, 60×g, 20°C). 
 
RNA preparation, microarray analysis and qPCR 
 Total RNA was prepared from NVMs using RNA Bee (AMS Biotechnology Ltd) 
according to the manufacturer's instructions.  For microarray studies of AVM RNA 
expression profiles, cardiomyocytes were homogenized in Tri Reagent® (Sigma Aldrich).  
Chloroform (0.2 ml) was added and samples vortexed, then centrifuged and the upper 
aqueous layer was collected.  An equal volume of 70% (v/v) ethanol was added and the 
RNA was purified using Qiagen RNeasy Mini Kits according to the manufacturer's 
instructions.  RNA was eluted in RNase-free water.  For qPCR analysis of AVM mRNAs, 
cardiomyocytes were pelleted and resuspended in RNA Bee and samples processed as for 
NVMs.  RNA purity was assessed from the A260/A280 (values of 1.9–2.1 were considered 
acceptable).  RNA concentrations were determined from the A260.   
 For microarrays, two separate samples were prepared from each of three 
preparations for hybridisation (i.e. 6 samples were hybridised for each of NVMs and AVMs).  
For NVMs, equal amounts of RNA from three individual preparations were pooled to 
generate a single sample.  For AVMs, RNA was prepared from cardiomyocytes from a single 
heart.  cRNA was prepared as previously described.1  Fragmentation of antisense cRNA and 
hybridization to Affymetrix rat genome 230 2.0 arrays was performed at the CSC/IC 
Microarray Centre (Imperial College London) according to the manufacturer's instructions.  
Data were exported to ArrayExpress (ArrayExpress ID: E-MTAB-2832). 
 qPCR was performed as previously described.1  cDNAs were synthesized using High 
Capacity cDNA Reverse Transcription Kits with random primers (Applied Biosystems) 
according to the manufacturer's instructions.  Primers were from Eurofins (glyceraldehyde 3-
phosphate dehydrogenase, Gapdh) or PrimerDesign (Supplemental Table 1).  qPCR was 
performed using an ABI Real-Time PCR 7500 system (Applied Biosystems).  Optical 96-well 
reaction plates were used containing (in each well) 12.5 µl iTaq Universal SYBR Green 
Supermix (Bio-Rad Laboratories Inc.), 5 µl primers and 7.5 µl (1 µg) cDNA template.  qPCR 
was performed using absolute quantification with standard curve protocol at 50°C (2 min), 
95°C (10 min) and then 40 cycles of 95°C (15 s) and 60°C (1 min).  Dissociation curve 
analysis was performed to confirm the absence of aberrant amplification products.  Values 
for selected RNAs were normalized to Gapdh expression. 
 
Microarray data analysis: rat cardiomyocytes 
 Microarray data (.CEL files) were imported into GeneSpring 12.6.1 (Agilent 
Technologies) using the PLIER16 algorithm with normalisation per gene to the gene median.  
For cardiomyocytes, probesets were filtered by expression removing those below the lowest 
20th percentile in all samples for either NVMs or AVMs.  Probesets within the array that 
detected protein kinases were identified.  Gene identities were confirmed by BLAST search 
of probeset target sequences using the Entrez nucleotide database 
(www.ncbi.nlm.nih.gov/BLAST).  Expressed kinases (i.e. those above the lowest 20th 
percentile of the full dataset) were selected.  Differentially expressed kinases in NVMs vs 
AVMs were identified (>2-fold difference; moderated T test with a Benjamini and Hochberg 
false discovery rate correction, p<0.05).   
 
Microarray data analysis: human myocardial samples 
 To identify changes in kinase mRNA expression in human failing hearts, we mined 
existing datasets publicly available from ArrayExpress or GEO databases (E-GEOD-57338,4 
E-GEOD-29819,5 E-GEOD-26887,6 E-GEOD-21610,7 E-GEOD-1145 and E-GEOD-54068).  
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Information on the patients from each of these studies is provided in Supplemental Table 2.  
No additional human myocardial samples were taken.  The data were downloaded as .CEL 
files (E-GEOD-57338, E-GEOD-29819, E-GEOD-26887, E-GEOD-21610) or normalised 
data (E-GEOD-1145, E-GEOD-5406) 
 For E-GEOD-57338, the following groups were analysed separately: females, non-
failing (NF) vs dilated cardiomyopathy (DCM); females, NF vs ischaemic heart failure (IHF); 
males, NF vs DCM; males, NF vs IHF.  Data were imported and analysed using GeneSpring 
13.0 using the PLIER16 algorithm with normalisation per gene to the gene median.  
Probesets within the array that detected protein kinases were identified and gene identities 
were confirmed by BLAST search of probeset target sequences using the Entrez nucleotide 
database (www.ncbi.nlm.nih.gov/BLAST).  Expressed kinases (i.e. those above the lowest 
20th percentile) were selected.  Differentially expressed kinases in each of the four groups 
were identified (>1.25-fold difference; p<0.05, moderated T test with a Benjamini and 
Hochberg false discovery rate correction).  The same approach was used for the other 
datasets but, because sample numbers were much less, all data in each dataset were 
imported and analysed together with no distinction between males and females.  Kinase 
mRNAs that were significantly changed in E-GEOD-57338 were clustered according to the 
number of groups in which they were identified and those that changed in 3 or 4 of the 
groups were selected.  The data for these kinases were mined from the other datasets for 
independent analysis. 
 
Analysis of the kinase proteome 
 NVMs were dissociated from ventricles from 2-3 d rats as previously described.1  
Cells were pre-plated (to remove non-cardiomyocytes) on plastic tissue culture dishes (45 
min, 37°C) in Dulbecco's modified Eagle's medium (DMEM)/medium 199 [4:1 (v/v)] 
containing 15% (v/v) FCS and 100 units/ml penicillin and streptomycin.  Non-adherent cells 
were collected and recovered by centrifugation (5 min, 60×g, 20°C).  AVMs were prepared 
as previously described15 and collected and initially washed under gravity.  Cell pellets were 
then washed in warmed PBS (37°C, 3 × 5 ml) with collection by centrifugation (5 min, 60×g, 
20°C).  Pellets were frozen and stored at -80°C.  Two independent cardiomyocyte samples 
(NVM samples were prepared from 15 rat hearts for each preparation; AVM samples were 
from a single heart each) were shipped to ActivX Biosciences for in situ kinase profiling 
using the KiNative™ platform as described in 9,10.  ATP and ADP acyl-nucleotide probes 
were synthesized as described previously.10  Cell pellets were lysed by sonication in lysis 
buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 0.1% Triton-X-100, phosphatase inhibitors 
[Cocktail II AG Scientific #P-1518]).  After lysis, samples were cleared by centrifugation and 
supernatants collected for probe-labeling.  Desthiobiotin-adenosine triphosphate-
acylphosphate probe (ATP probe; 50 µl of 10× aqueous solution) was added to each sample 
to give a final concentration of 5 µM, and incubated with the samples for 10 minutes.  
Samples were prepared for MS analysis as described previously.10,11  Briefly, probe-labeled 
lysates were denatured and reduced in [6 M urea, 10 mM dithiothreitol (DTT); 65°C, 15 min], 
alkylated (40 mM iodoacetamide, 37°C, 30 min), and gel filtered (BioRad 10DG) into 10 mM 
ammonium bicarbonate, 2 M urea, 5 mM methionine. The desalted protein mixture was 
digested with trypsin (0.015 mg/ml; 1 h, 37°C), and desthiobiotinylated peptides captured 
using high-capacity streptavidin resin (12.5 µl; Thermo Scientific). Captured peptides were 
washed extensively (150 μl per wash) with three different wash buffers: (A) 10 times with 1% 
(v/v) Triton X100, 0.5% tergitol, 1 mM ethylene diamine tetra-acetic acid (EDTA) in 
phosphate buffered saline (PBS); (B) 60 times with PBS; (C) 15 times with HPLC grade 
water. Peptides were eluted from the streptavidin beads using two 35 μl washes of a 50% 
CH3CN/water mixture containing 0.1% trifluoroacetate (TFA) at room temperature. 
 Samples were analyzed by LC-MS/MS as described previously.10  Samples were 
analyzed on Thermo LTQ ion trap mass spectrometers coupled with Agilent 1100 series 
micro-HPLC systems with autosamplers, essentially as described,11 using a custom target 
list comprising 321 unique rat kinase peptides that had been previously identified during the 
characterization of various samples in data dependent mode.9  For signal 
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extraction/quantitation, typically up to four ions were selected for based on their presence, 
intensity, and correlation to the reference MS/MS spectrum.  The resulting chromatographic 
peaks from each run were then integrated.  Each sample was analysed in duplicate.  The 
means of the integrated peak values were calculated for each peptide in each sample 
(NVM1, NVM2, AVM1, AVM2).  When multiple peptides were derived from a single kinase, 
MS values were added.  For peptides that were not unique, the values were allocated 
according to the proportion of signals for unique peptides where possible.  The means of the 
replicates were used to give an average estimate for NVMs and AVMs.  The MS value for 
each kinase was expressed as the percentage of the total MS integration values for NVMs or 
AVMs. 
 
Western blotting 
 Recombinant human MKK1 (gene symbol MAP2K1) and p38-MAPKα (MAPK14) 
were expressed as glutathione S-transferase (GST) fusion proteins and were prepared as 
previously described.12-14  Other recombinant human GST-fusion proteins were obtained 
commercially (AKT1, R & D Systems, 1775-KS-010; RIPK1, Abnova, H00008737-P01; 
PKN2 Life Technologies Ltd., PV3879).  Concentrations of recombinant proteins were 
determined relative to bovine serum albumin (BSA) standards on Coomassie Brilliant Blue-
stained gels.  Cardiomyocyte samples were prepared for immunoblotting as previously 
described.1  Protein concentrations were determined by Bio-Rad Bradford assay using BSA 
standards.  Proteins (cardiomyocytes and recombinant protein standards) were separated by 
SDS-polyacrylamide gel electrophoresis on 10% or 8% (w/v) polyacrylamide gels and 
transferred electrophoretically to nitrocellulose. Proteins were detected as previously 
described1 using primary antibodies as indicated in Supplemental Table 3.  Bands were 
detected by enhanced chemiluminescence using ECL Prime Western Blotting detection 
reagents with visualisation using an ImageQuant LAS4000 system (GE Healthcare). 
ImageQuant 7.0 software (GE Healthcare) was used for densitometric analysis of the bands.  
Data analysis used GraphPad Prism version 4.0.   
 
Immunostaining 
 NVMs were plated at 1.5×106 cells/dish on 35 mm Primaria dishes containing glass 
coverslips pre-coated with sterile 1% (w/v) gelatin followed by laminin (20 µg/ml in PBS; 
Sigma-Aldrich UK) in DMEM/medium [4:1 (v/v)] containing 100 units/ml penicillin and 
streptomycin and 15% (v/v) foetal calf serum.  The plating medium was withdrawn and cells 
were incubated in serum-free maintenance medium (DMEM/medium [4:1 (v/v)], 100 units/ml 
penicillin and streptomycin) for a further 24 h.  Cells were washed with ice-cold PBS and 
fixed in 3.7% (v/v) formaldehyde in PBS (10 min, room temperature). Cardiomyocytes were 
permeabilised with 0.1% (v/v) Triton X-100 (10 min, room temperature) in PBS and non-
specific binding blocked with 1% (w/v) fatty acid free BSA in PBS containing 0.1% (v/v) 
Triton X-100 (10 min, room temperature). All incubations were at 37°C in a humidified 
chamber, and coverslips were washed three times in PBS after each stage of the 
immunostaining procedure. Cardiomyocytes were stained with mouse monoclonal primary 
antibodies to troponin T (1/40, 60 min; Stratech Scientific, Cat. no. MS-295-P1) with anti-
mouse immunoglobulin secondary antibodies coupled to Alexa-Fluor 488 (1/200, 60 min; 
Invitrogen).  Myofilamentous actin was counterstained with Texas Red®-X phalloidin 
(5 U/ml, 20 min; Life Technologies Inc.).  Coverslips were mounted using fluorescence 
mounting medium (Dako) and viewed with a Zeiss Axioskop fluorescence microscope using 
a 40× objective. Digital images captured using a Canon PowerShot G3 camera were 
reduced in size and superimposed using Adobe Photoshop 7.0. 
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Supplemental Table 1.  Primers used for qPCR. 
 
Gene 
symbol Accession no. 
Product 
length (bp) 
 
Position 
 
Sense primer 
 
Antisense primer 
Cdc42bpa NM_053657 129 24-152 TCCCTCCCCCTCCATACATT GCAACATAATCCTGAAACGAATCC 
Cdc42bpb NM_053620 104 2282-2385 GAGGTCCTGATGCTGAAAGATAAG CTCTCCCGTTCGTACTTGTCT 
Dmpk XM_006223105 119 1731-1849 TACAGGAGCGGATGGAGATG TGCCCCAGGGTTCATACAC 
Gapdh NM_017008.3 93 552-644 CCAAGGTCATCCATGACAACTT AGGGGCCATCCACAGTCTT 
Grk5 NM_030829 91 230-320 GGGAAGGGGGTGGAGGAA CGGAGGTCTTCACACTGGTT 
Lats1 NM_001134543 116 5150-5265 GGAGGAATTGTGGAGTCATAAC ATGTTAATAAGCCTTACGAAAATGAA 
Lats2 NM_001107267 95 1742-1836 ACAAAAAGCAGATCCAGACCTC ATATGGGGAGTAACTCTTGATTCG 
Map2k3 NM_001100674 85 1292-1376 TTCTGGTCCTGGGCATTCG AGGTCTGATTCTTTGGCACTTG 
Map2k6 NM_053703 94 299-392 CGGGGTGGTGGAGAAGATG CCGTTTCTGCTCCTGGCTAT 
Mapk12 NM_021746 118 1393-1510 GTGCTTTTATCCCAAGTCATCCA TGTTCTGCCAGGGTCATCTC 
Mapk14 NM_031020 112 1308-1419 CGAATGGAAGAGCCTGACCTA TGAAGTGGGATGGACAGAACA 
Mapkapk2 NM_178102 95 1734-1828 GTCCTTTTCCCCACTCCTCAT CATCCCTATAACAACCTCCACAAT 
Mast1 NM_181089 116 220-335 GCCCATTTCTCGTTTGCTTCT CAGGAGGATGAGACGGTTGAG 
Mast2 NM_001108005 98 719-816 CAGTCTCTTCATCGTGTTCCTC TGTGCTAAAATGCTTCGTCAGA 
Mast3 NM_001134796 94 2181-2274 AGGGTGACGAGACGAATGAC TCGGAACTGCTGTAGACCTTG 
Mast4 XM_006231870 114 8176-8289 GAGGGCACACAGGGACTTA CTTCTTGGACTCACAGCGTAA 
Myh6 NM_017239 93 1865-1957 TACCAGAAGTCCTCCCTCAAAC CTTGCCTCCTTTGCCTTTCC 
Myh7 NM_017240 124 4186-4309 TGGCTCAGAGGCTTCAGGA CGCTCCACATCCACCATCA 
Orc1 NM_177931 105 1085-1189 CTTCTCTTCGTGCCCGTAGA ACTCTTCCTCTTCTTGGTCACTT 
Orc2 NM_001012003 96 678-773 CGAAAAAGAGTCAAGGTCAGAATAG CCAAGTCACCTGCTTTGTCTC 
Orc3 NM_001025282 147 751-897 ATCGCCACATCTCCTGTTATTATC AAAGGGAAACTGAGGGGTAAGAA 
Orc4 NM_199092 113 517-629 CCTTTCGTTTCTTCTGGAAGC GGAGTGTTTGGTTTTTCTGATGA 
Orc5 NM_001014186 121 904-1024 CGCAGTGGGAAACATTACAGAA GCAAGGTACGCAGCAATAAGAA 
Orc6 NM_001033690 89 930-1018 AACAACCAGCAAAAGACATAGAAG TTTCCATTCCTCATAATCCTGTGT 
Pkn1  NM_017175 85 1891-1975 CTGCCCTCCACCTCATGTAG GGGTCTCCTGGGTCTCTGAA 
Pkn2 NM_001105755 105 1923-2027 GCTATTCCCACAGTAAATCATTCTG GGCTGGAGGTGCGAGTTC 
Pkn3 NM_001047861 125 2122-2246 CACCCGTTCTTGCTCTCTCT TGGGGCTCAGGAAAGACATC 
Prkcd NM_133307 105 2133-2237 GTAACAGGAAACATCAGGCTTCA AGGGGATTTCACTTTGGGCTTA 
Prkce NM_017171 91 1582-1672 GCGGAAACACCCTTATCTAACC GTCTCCACCGTTTACATATTCCAT 
Prkci NM_032059 86 1252-1337 GAGCGAGGGATAATTTATAGAGATTTG ATGCCGTAGTCAGTGAGTTTG 
Sgk1 NM_001193568 76 338-413 CAGGAGCCCGAACTTATGAAC AGGATGGACCCAGGTTGATTT 
Sgk2 NM_134463 75 1052-1126 CGTGGTACTGACAGATTTCGG GTGCCGCAGAAGGTGGAT 
Stk38 NM_001015025 121 105-225 TTCCCCTGCCTCCCACTG ATCAAGTCCTAATCACAACGCATAA 
Stk38l NM_001083336 130 784-913 CGGGACATCAAGCCAGACA GTGGGTTGTGTGTGAGGTTTC 
Tnni1 NM_017184 104 223-326 CGCCCTTCAGGACTTATGC TGATCTCTCTCGTGTTGTGGA 
Tnni3 NM_017144 110 204-313 GCCACATGCCAAGAAAAAGTC GTCGCTCCTCTGCCTCAC 
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Supplemental Table 2.  Affymetrix microarray datasets used for analysis of kinase mRNA 
expression in human heart failure.  NF, non-failing. DCM, dilated cardiomyopathy.  IHF, 
ischaemic heart failure.  NDHF, non-diabetic heart failure. DHF, diabetic heart failure.  ARVC, 
arrhythmogenic right ventricular cardiomyopathy. * left ventricular samples studied (i.e. right 
ventricular samples not included in analysis).  ** analysis performed only on samples before 
ventricular assist device support.  # Hannenhalli et al. report that 86 IHF samples and 108 DCM 
samples were studied, but the annotations indicate 108 IHF and 86 DCM.  For this study, the 
dataset annotations were used. 
 
 
ArrayExpress/GEO 
accession no. 
Patients studied 
(n) 
Technology Reference 
E-GEOD-57338 
GSE57338 
Female NF (63) 
Female DCM (19) 
Female IHF (14) 
Male NF (73) 
Male DCM (63) 
Male IHF (81) 
Affymetrix Human Gene 1.1 
ST Array 
Liu et al, 2015 
E-GEOD-26887 
GSE26887 
NF (5) 
NDHF (12) 
DHF (7) 
Affymetrix Human Gene 1.0 
ST Array 
Greco et al, 2012 
E-GEOD-29819 * 
GSE29819 
NF (6) 
DCM (7) 
ARVC (6) 
Affymetrix Human Genome 
U133 Plus 2.0 Array 
Gaertner et al, 2012 
E-GEOD-21610 ** 
GSE21610 
NF (8) 
DCM (21) 
IHF (9) 
Affymetrix Human Genome 
U133 Plus 2.0 Array 
Schwientek et al, 2010 
E-GEOD-1145 
GSE1145 
NF (11) 
DCM (27) 
IHF (31) 
Affymetrix Human Genome 
U133 Plus 2.0 Array 
Not available 
E-GEOD-5406 # 
GSE5406 
NF (16) 
DCM (86) 
IHF (108) 
Affymetrix Human Genome 
U133A Array 
Hannenhalli et al, 2006 
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Supplemental Table 3.  Antibodies used for immunoblotting. 
 
 
Target Source Catalogue no. Dilution 
AKT1/2/3 Cell Signaling Technology 4691 1/1000 
BRaf (H145) Santa Cruz Biotechnology Inc. sc-9002 1/750 
ERK1/2 Cell Signaling Technology 4695 1/1000 
MAP3K8 (M20) Santa Cruz Biotechnology Inc. sc-720 1/1000 
MAP4K4 (HGK) Cell Signaling Technology 3485 1/750 
MKK1/2 Cell Signaling Technology 8727 1/1000 
MST1 Cell Signaling Technology 3682 1/1000 
MST3 BD Transduction Laboratories 611056 1/1000 
p38-MAPK Cell Signaling Technology 9212 1/1000 
PKCδ BD Transduction Laboratories 610397 1/500 
PKN1 BD Transduction Laboratories 610686 1/1000 
PKN2  Cell Signaling Technology 2612 1/750 
RIPK1 Cell Signaling Technology 4926 1/1000 
RIPK2 Cell Signaling Technology 4142 1/1000 
TNNI3K Sigma SAB4502101 1/500 
ZAK Thermo Scientific PA5-29317 1/1000 
HRP-anti-mouse 
immunoglobulins 
Dako P0260 1/5000 
HRP-anti-rabbit 
immunoglobulins 
Dako P0448 1/5000 
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Supplemental Table 4.  Protein kinases not detected in ActivX proteomics experiment but detected 
by microarrays: kinases with protein expression in cardiomyocytes confirmed in previous studies.  
Where possible, references to initial reports are given.  Reviews are cited for some kinases that are well-
studied in cardiomyocytes.  We apologise to the many other investigators whose work is not mentioned. 
 
* Not detected in proteomics experiment; other kinases were not searched for.   
# Identified in embryonic development. 
 
Gene 
symbol Gene name 
Microarrays 
(raw fluorescence values) 
Reference 
  AVMs NVMs  
Adrbk2* Adrenergic, beta, receptor kinase 2 95 26 Vinge et al. 1 
Akt1* 
v-Akt murine thymoma viral oncogene 
homolog 1 1022, 1868 686, 1709 
DeBosch et al. 2  
Liu et al. 3 
Akt2 
v-Akt murine thymoma viral oncogene 
homolog 2 
378, 473, 
600 
268, 327, 
510 DeBosch et al. 4 
Alpk3 # Alpha-kinase 3 959 505 Hosoda et al. 5 
Bmpr1a 
Bone morphogenetic protein receptor, 
type IA 121, 262, 42 
338, 519, 
155 Sui et al. 6 
Bmpr2 
Bone morphogenetic protein receptor, 
type II (serine/threonine kinase) 
237, 253, 
146 
156, 223, 
260 Sui et al. 6 
Camk2b 
Calcium/calmodulin-dependent protein 
kinase II beta 61 96 Singh et al. 7 
Camk2d 
Calcium/calmodulin-dependent protein 
kinase II delta 
112, 1354, 
341 
135, 707, 
217 Xu et al. 8 
Cdk8 Cyclin-dependent kinase 8 118 276 Kim et al. 9 
Csf1r* Colony stimulating factor 1 receptor 63 89 Postiglione et al. 10  
Dapk3 Death-associated protein kinase 3 383 759 Chang et al. 11 
Ddr2 
Discoidin domain receptor tyrosine 
kinase 2 50, 28, 86 
238, 203, 
543 Grigore et al. 12 
Dmpk Dystrophia myotonica-protein kinase 3206 1186 Mussini et al. 13 
Dyrk2 
Dual-specificity tyrosine-(Y)-
phosphorylation regulated kinase 2 
251, 217, 
372 
245, 249, 
360 Weiss et al. 14 
Epha3 Eph receptor A3 41, 64, 92 
61, 113, 
160 Li et al. 15 
Erbb3 # 
v-Erb-b2 erythroblastic leukemia viral 
oncogene homolog 3 (avian) 54, 75 57, 59 Hao et al. 16 
Fgfr1 Fibroblast growth factor receptor 1 333, 279, 95 
746, 490, 
229 Liu et al. 3 
Fgfr2 Fibroblast growth factor receptor 2 
66, 48, 100, 
48 
99, 187, 
121, 56 Liu et al. 3 
Fgfr3 Fibroblast growth factor receptor 3 37, 57 55, 86 Liu et al. 3 
Flt1* FMS-related tyrosine kinase 1 
144, 124, 
128, 258, 
174 
117, 73, 79, 
107, 92 Takahashi et al. 17 
Grk4* G protein-coupled receptor kinase 4 148 83 Dzimiri et al. 18 
Grk6* G protein-coupled receptor kinase 6 123, 48, 125 
148, 76, 
312 
Dzimiri et al. 18  
Yi et al. 19 
Hspb8 Heat shock protein B8 1509, 1863 839, 1367 Sui et al. 6 
Igf1r Insulin-like growth factor 1 receptor 
80, 48, 156, 
77 
220, 95, 
383, 1312 Leri et al. 20 
Ikbkb* 
Inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase beta 107 164 Dhingra et al. 21 
Insr Insulin receptor 99, 172, 74 85, 146, 89 van Echten et al. 22 
Jak2* Janus kinase 2 58, 78 402, 407 McWhinney et al. 23 
Kdr* Kinase insert domain receptor 676 446 Takahashi et al. 17 
Kit # 
v-Kit Hardy-Zuckerman 4 feline sarcoma 
viral oncogene homolog 51 84 
Torella et al. 24 
Leri et al. 25 
Lck* 
Lymphocyte-specific protein tyrosine 
kinase 93 95 Ping et al. 26 
Map3k8 Mitogen-activated protein kinase kinase 193 72 Kim et al. 27 
10 
 
kinase 8 
Mapk11
* Mitogen-activated protein kinase 11 60 62 Kim et al. 28 
Met # Met proto-oncogene 49 44 Rappolee et al. 29 
Mknk1 
MAP kinase-interacting serine/threonine 
kinase 1 175 142 Tuxworth et al. 30 
Mknk2 
MAP kinase-interacting serine/threonine 
kinase 2 1018 815 Tuxworth et al. 30 
Mylk3 Myosin light chain kinase 3 3341, 1876 829, 501 Ai et al. 31 
Ntrk2 
Neurotrophic tyrosine kinase, receptor, 
type 2 17, 58 101, 166 Okada et al. 32  
Ntrk3 
Neurotrophic tyrosine kinase, receptor, 
type 3 69 64 
Kawaguchi-Manabe 
et al. 33 
Obscn 
Obscurin, cytoskeletal calmodulin and 
titin-interacting RhoGEF 516 82 Borisov et al. 34 
Pak1 
p21 protein (Cdc42/Rac)-activated 
kinase 1 105 128 Clerk et al. 35 
Pak2* 
p21 protein (Cdc42/Rac)-activated 
kinase 2 
99, 421, 96, 
156 
188, 701, 
104, 450 Kim et al. 27 
Pdgfrb 
Platelet derived growth factor receptor, 
beta polypeptide 113, 49, 35 
991, 78, 
185 Chintalgattu et al. 36 
Pdk1 
Pyruvate dehydrogenase kinase, 
isozyme 1 
1466, 1021, 
1437 
414, 325, 
283 Puthanveetil et al. 37 
Pdk2 
Pyruvate dehydrogenase kinase, 
isozyme 2 2083, 841 546, 179 Puthanveetil et al. 37 
Pdk4 
Pyruvate dehydrogenase kinase, 
isozyme 4 1003, 2329 57, 89 Puthanveetil et al. 37 
Pdpk1 
3-phosphoinositide dependent protein 
kinase 1 305 395 Rubio et al. 38 
Pim1 Pim-1 oncogene 196 161 Muraski et al. 39 
Pim3 Pim-3 oncogene 1137 323 Liu et al. 40 
Pink1 PTEN induced putative kinase 1 1110, 3869 332, 1025 Billia et al. 41 
Plk1 Polo-like kinase 1 106 122 Coxon et al. 42 
Prkca* Protein kinase C, alpha 112, 141 130, 250 Clerk et al. 43 
Prkcb* Protein kinase C, beta 54 85 Bowling et al. 44 
Prkcd Protein kinase C, delta 271 568 Clerk et al. 43 
Prkce* Protein kinase C, epsilon 364, 664 170, 215 Clerk et al. 43 
Prkg1 Protein kinase, cGMP-dependent, type I 217 233 Wollert et al. 45 
Ptk2b* PTK2B protein tyrosine kinase 2 beta 38 137 Bayer et al. 46 
Ripk1 
Receptor (TNFRSF)-interacting serine-
threonine kinase 1 156, 75 164, 98 This study 
Ripk2 
Receptor-interacting serine-threonine 
kinase 2 256 189 This study 
Rps6ka
2 
Ribosomal protein S6 kinase 
polypeptide 2 175 147 Li et al. 47 
Sgk1 Serum/glucocorticoid regulated kinase 1 1335 453 Aoyama et al. 48 
Speg  SPEG complex locus 518 193 Liu et al. 49 
Taf1 
TAF1 RNA polymerase II, TATA box 
binding protein (TBP)-associated factor 82 130 Servant et al. 50 
Tec* Tec protein tyrosine kinase 96 114 Bony et al. 51 
Tgfbr1* 
Transforming growth factor, beta 
receptor 1 69, 90 83, 256 Devaux et al. 52 
Tnni3k TNNI3 interacting kinase 1304 180 Vagnozzi et al. 53 
Ttn Titin 4538 773 Hidalgo et al. 54  
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Supplemental Table 5.  Protein kinases not detected in ActivX proteomics experiment but detected 
by microarrays: kinases with protein expression confirmed in hearts in previous studies.  We 
apologise to any other investigators whose work is not mentioned. 
 
* Not detected in proteomics experiment; other kinases were not searched for.   
# Identified in global proteomics studies only 
 
Gene 
symbol Gene name 
Microarrays 
(raw fluorescence values) 
References 
  AVMs NVMs  
Aak1 *# AP2 associated kinase 1 
204, 97, 76, 
32, 81 
272, 83, 129, 
50, 59 
Aye et al. 1 
Fernandez-Sanz et al. 2 
Lundby et al. 3 
Su et al. 4 
Abl2 # 
v-Abl Abelson murine leukemia viral 
oncogene 2 (arg, Abelson-related 
gene) 78 142 
Fernandez-Sanz et al. 2 
Lundby et al. 3 
Acvrl 1# Activin A receptor type II-like 1 68 108 Lundby et al. 3 
Adck1 # Aarf domain containing kinase 1 109 127 
Fernandez-Sanz et al. 2 
Lundby et al. 3 
Adck3 # Aarf domain containing kinase 3 1963 282 Lundby et al. 3 
Adck5 # Aarf domain containing kinase 5 99 136 Fernandez-Sanz et al. 2 
Akt3 
v-Akt murine thymoma viral 
oncogene homolog 3  61, 31, 39 102, 113, 75 Taniyama et al. 5  
Alpk2 # Alpha-kinase 2 899 402 Su et al. 4 
Axl * Axl receptor tyrosine kinase 134 690 Batlle et al. 6  
Blk * B lymphoid tyrosine kinase 70, 332 50, 159 Ping et al. 7 
Bmp2k # BMP2 inducible kinase 87 235 Lundby et al. 3 
Bub1 # 
Budding uninhibited by 
benzimidazoles 1 homolog (S. 
cerevisiae) 32 118 Fernandez-Sanz et al. 2 
Camk1g # 
Calcium/calmodulin-dependent 
protein kinase IG 121 57 Fernandez-Sanz et al. 2 
Camk2a * 
Calcium/calmodulin-dependent 
protein kinase II alpha 151 76 
Aye et al. 1 
Lundby et al. 3  
Bayer et al. 8 
Cdc42bpa 
# 
CDC42 binding protein kinase 
alpha 126 163 
Fernandez-Sanz et al. 2 
Lundby et al. 3 
Cdk12 # Cyclin-dependent kinase 12 106, 39 160, 80 
Fernandez-Sanz et al. 2 
Lundby et al. 3 
Cdk14 # Cyclin-dependent kinase 14 341, 43 481, 100 Fernandez-Sanz et al. 2 
Cdk18 # Cyclin-dependent kinase 18 143, 106 89, 103 Fernandez-Sanz et al. 2 
Epha5 # Eph receptor A5 85 44 Lundby et al. 3 
Epha6 Eph receptor A6 53 49 DuSablon et al. 9 
Fastk # 
Fas-activated serine/threonine 
kinase 528 376 Fernandez-Sanz et al. 2 
Fastkd2 # FAST kinase domains 2 201 165 Fernandez-Sanz et al. 2 
Fastkd5 # FAST kinase domains 5 98 120 Fernandez-Sanz et al. 2 
Fgr * 
Gardner-Rasheed feline sarcoma 
viral (v-fgr) oncogene homolog 63 79 Ping et al. 7  
Gak *# Cyclin G associated kinase 151 520 Lundby et al. 3 
Hipk1 # 
Homeodomain interacting protein 
kinase 1 381 471 Fernandez-Sanz et al. 2 
Hipk3 # 
Homeodomain interacting protein 
kinase 3 231, 88 232, 47 Lundby et al. 3 
Hunk # 
Hormonally upregulated Neu-
associated kinase 80 91 Fernandez-Sanz et al. 2 
Irak3 # 
Interleukin-1 receptor-associated 
kinase 3 37 334 Fernandez-Sanz et al. 2 
Jak3 *# Janus kinase 3 105 166 Lundby et al. 3 
Kalrn # Kalirin, RhoGEF kinase 187, 206 124, 240 Lundby et al. 3 
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Lrrk1 # Leucine-rich repeat kinase 1 78 108 Fernandez-Sanz et al. 2 
Map2k5 
Mitogen activated protein kinase 
kinase 5 137 250 
Nicol et al. 10 
Lundby et al. 3 
Map3k14 
# 
Mitogen-activated protein kinase 
kinase kinase 14 102 145 Lundby et al. 3 
Mapk4  Mitogen-activated protein kinase 4 55 86 Dingar et al. 11 
Mapk6 Mitogen-activated protein kinase 6 461 722 Dingar et al. 11 
Mapkapk
3 * 
Mitogen-activated protein kinase-
activated protein kinase 3 155 139 
Aye et al. 1 
Moise et al. 12 
Mapkapk
5 
Mitogen-activated protein kinase-
activated protein kinase 5 148 174 Dingar et al. 11 
Melk # 
Maternal embryonic leucine zipper 
kinase 37 86 Lundby et al. 3 
Mylk2 *# Myosin light chain kinase 2 376 295 Lundby et al. 3 
Mylk4 
Myosin light chain kinase family, 
member 4 104 109 Herrer et al. 13   
Nek3 # NIMA-related kinase 3 82 126 Lundby et al. 3 
Pak3 
p21 protein (Cdc42/Rac)-activated 
kinase 3 49 64 Buscemi et al. 14 
Pak4 
p21 protein (Cdc42/Rac)-activated 
kinase 4 134 205 Nekrasova et al. 15 
Pak6 # 
p21 protein (Cdc42/Rac)-activated 
kinase 6 251 161 Lundby et al. 3 
Pdk3 # 
Pyruvate dehydrogenase kinase, 
isozyme 3 56, 46 283, 206 
Fernandez-Sanz et al. 2 
Lundby et al. 3 
Peak1 # NKF3 kinase family member 102 175 
Fernandez-Sanz et al. 2 
Lundby et al. 3 
Pragmin # Pragma of Rnd2 39 68 Lundby et al. 3 
Prkcg * Protein kinase C, gamma 69 54 Liu et al. 16  
Prkch Protein kinase C, eta 79, 154 49, 74 
Lundby et al. 3 
Ping et al. 17 
Prkx Protein kinase, X-linked 129, 101 214, 133 Li et al. 18  
Riok1 # RIO kinase 1 (yeast) 102 165 Lundby et al. 3 
Ripk4 *# 
Receptor-interacting serine-
threonine kinase 4 98 98 Lundby et al. 3 
Ror1 # 
Receptor tyrosine kinase-like 
orphan Receptor 1 20 130 Fernandez-Sanz et al. 2 
Srpk2 # SRSF protein kinase 2 206 372 
Fernandez-Sanz et al. 2 
Lundby et al. 3 
Srpk3 # SRSF protein kinase 3 218 102 Lundby et al. 3 
Tek # TEK tyrosine kinase, endothelial 327 203 Lundby et al. 3 
Tie1 * 
Tyrosine kinase with 
immunoglobulin-like and EGF-like 
domains 1 512 252 
 
Fernandez-Sanz et al. 2 
Shyu 19 
Trib3 Tribbles homolog 3 (Drosophila) 19, 20, 53 
191, 332, 
295 Ti et al. 20 
Trpm7 # 
Transient receptor potential cation 
channel, subfamily M, member 7 97, 99 234, 278 Lundby et al. 3 
Wnk3 # 
WNK lysine deficient protein kinase 
3 39 55 Fernandez-Sanz et al. 2 
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Supplemental Table 6.  Protein kinases not detected in ActivX proteomics experiment but detected 
by microarrays: kinases with mRNA expression only confirmed in hearts in previous studies.  We 
apologise to any other investigators whose work is not mentioned. 
 
* Not detected in proteomics experiment; other kinases were not searched for.   
 
Gene 
symbol Gene name 
Microarrays 
(raw fluorescence values) 
mRNA 
expression Reference 
  AVMs NVMs   
Clk1 CDC-like kinase 1 832 465 +++ Xie et al. 1 
Clk4 CDC-like kinase 4 173 211 +++ Schultz et al. 2 
Dapk2 Death-associated kinase 2 110 71 +++ Kawai et al. 3  
Dclk2* Doublecortin-like kinase 2 142 145 + Ohmae et al. 4  
Ddr1 
Discoidin domain receptor 
tyrosine kinase 1 134, 253 284, 532 
+ 
Di Marco et al. 5  
Dstyk 
Dual serine/threonine and 
tyrosine protein kinase 55, 64, 45 
118, 111, 
95 
++ 
Peng et al. 6  
Epha4 Eph receptor A4 
94, 39, 48, 
46 
153, 51, 56, 
88 
+ 
Dries et al. 7  
Epha7* Eph receptor A7 106, 34, 226 
120, 56, 
149 
+ 
Dries et al. 7 
Flt4 Fms-related tyrosine kinase 4 91 67 + Aprelikova et al. 8  
Hipk4 
Homeodomain interacting 
protein kinase 4 106 76 
++ 
Arai et al. 9 
Ick Intestinal cell kinase 154 303 ++ Abe et al. 10 
Mok MOK protein kinase 99 105 + Miyata et al. 11 
Pask 
PAS domain containing 
serine/threonine kinase 91 90 
+ 
Miao et al. 12  
Pbk PDZ binding kinase 39 106 ++ Gaudet et al. 13 
Prkg2 
Protein kinase, cGMP-
dependent, type II 30 68 
+ 
Uhler et al. 16 
Pxk 
PX domain containing 
serine/threonine kinase 84, 134 198, 293 
++ 
Mao et al. 17 
Ros1 
c-Ros oncogene 1 , receptor 
tyrosine kinase 103 40 
+++ Matsushime et al. 
18 
Ryk Receptor-like tyrosine kinase 260, 334 624, 710 + Wang et al. 19 
Stk17b Serine/threonine kinase 17b 73, 66, 170 
246, 182, 
281 
+++ 
Sanjo et al. 20 
Stk35 Serine/threonine kinase 35 173 170 ++ Vallenius et al. 21 
Stk36 Serine/threonine kinase 36 150, 413 99, 247 + Osterlund et al. 22 
Trib1 Tribbles homolog 1  312, 95, 621 
105, 45, 
209 
++ 
Okamoto et al. 23 
Trib2 Tribbles homolog 2  129, 306 214, 565 +++ Okamoto et al. 23 
Trio 
Triple functional domain 
(PTPRF interacting) 
41, 89, 183, 
210 
109, 208, 
380, 472 
+++ 
Debant 24 
Tssk2 Testis-specific serine kinase 2 61 39 + Hao et al. 25 
Uhmk1 
U2AF homology motif (UHM) 
kinase 1 225, 94 413, 121 
+ 
Maucuer et al. 26 
Ulk2 Unc-51 like kinase 2  160 161 +++ Yan et al.27 
Vrk1 Vaccinia related kinase 1 46 134 + Nezu et al. 28 
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Supplemental Table 7.  Protein kinases not detected in ActivX proteomics experiment but 
detected by microarrays: kinases for which there are no additional publications on 
expression in heart.   
 
* Not detected in proteomics experiment; other kinases were not searched for.   
 
 
Gene 
symbol Gene name 
Microarrays 
(raw fluorescence values) 
  AVMs NVMs 
Acvr1  Activin A receptor, type I 248, 469, 96 393, 265, 163 
Acvr2a Activin A receptor, type IIA 103, 127 190, 287 
Acvr2b Activin A receptor, type IIB 123 143 
Adck2 Aarf domain containing kinase 2 103 105 
Adck4 Aarf domain containing kinase 4 147 285 
Amhr2 Anti-Mullerian hormone receptor, type II 153 51 
Aurkc Aurora kinase C 133 169 
Bckdk Branched chain ketoacid dehydrogenase kinase 755 514 
Bcr Breakpoint cluster region 322, 274 298, 299 
Brsk1 BR serine/threonine kinase 1 37 179 
Brsk2 BR serine/threonine kinase 2 147 224 
Bub1b 
Budding uninhibited by benzimidazoles 1 homolog, 
beta (S. cerevisiae) 33 65 
Camkk1 
Calcium/calmodulin-dependent protein kinase 
kinase 1, alpha 87 122 
Camkv CaM kinase-like vesicle-associated 45, 112 54, 113 
Cdk19 Cyclin-dependent kinase 19 162 173 
Cdkl3 Cyclin-dependent kinase-like 3 45 50 
Dapk1 Death associated protein kinase 1 60, 24 516, 289 
Epha10 EPH receptor A10 30 53 
Epha8 Eph receptor A8 153 92 
Ephb6 Eph receptor B6 73 75 
Fastkd3 FAST kinase domains 3 73 114 
Gak* Cyclin G associated kinase 151 520 
Grk1 G protein-coupled receptor kinase 1 75 62 
Hck* Hemopoietic cell kinase 60 111 
Hipk2 Homeodomain interacting protein kinase 2 
1190, 109, 310, 
814 
509, 83, 129, 
268 
Insrr Insulin receptor-related receptor 141 200 
Jak3* Janus kinase 3 105 166 
Limk1* LIM domain kinase 1 88 105 
Limk2 LIM domain kinase 2 88 105 
Map3k12* Mitogen activated protein kinase kinase kinase 12 353 465 
Map3k9* Mitogen-activated protein kinase kinase kinase 9 70 86 
Mapk15 Mitogen-activated protein kinase 15 83 67 
Matk Megakaryocyte-associated tyrosine kinase 75 68 
Mertk* c-Mer proto-oncogene tyrosine kinase 65 101 
Mylk2* Myosin light chain kinase 2 376 295 
Nrbp2 Nuclear receptor binding protein 2 318 379 
Nrk Nik related kinase 19 269 
Pdgfra 
Platelet derived growth factor receptor, alpha 
polypeptide 66 1244 
Pik3r4 Phosphoinositide-3-kinase, regulatory subunit 4 144 277 
Pkdcc 
Protein kinase domain containing, cytoplasmic 
homolog (mouse) 344 310 
Pkn3 Protein kinase N3 258 196 
Plk3 Polo-like kinase 3 126 52 
Plk4 Polo-like kinase 4 27 76 
Plk5 Polo-like kinase 5 89 69 
Pskh1 Protein serine kinase H1 259 213 
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Ptk7 PTK7 protein tyrosine kinase 7 41 779 
Ret Ret proto-oncogene 51, 64, 77 76, 35, 162 
Riok2 RIO kinase 2 (yeast) 79 120 
Riok3 RIO kinase 3 (yeast) 283, 132, 163 728, 259, 353 
Sbk1 SH3-binding domain kinase 1 137, 238 75, 108 
Scyl1 SCY1-like 1 (S. cerevisiae) 152, 325 204, 432 
Scyl2 SCY1-like 2 (S. cerevisiae) 139 248 
Scyl3 SCY1-like 3 (S. cerevisiae) 61 69 
Sgk196 Protein kinase-like Protein SgK196 113, 53, 102 197, 62, 253 
Sik2* Salt-inducible kinase 2 54 76 
Stk19 Serine/threonine kinase 19 38 107 
Stk32c Serine/threonine kinase 32C 53 38 
Stk40 Serine/threonine kinase 40 272 207 
Stradb STE20-related kinase adaptor beta 418 263 
Tbrg4 Transforming growth factor beta regulator 4 496, 198 401, 171 
Tesk2 Testis-specific kinase 2 50 69 
Tex14 Testis expressed 14 69, 90 83, 256 
Tp53rk TP53 regulating kinase 59, 54, 98 72, 108, 118 
Ttbk2* Tau tubulin kinase 2 83 90 
Ttk Ttk protein kinase 38 73 
Tyro3* TYRO3 protein tyrosine kinase 29 127 
Vrk3 Vaccinia related kinase 3 371 316 
Zap70* Zeta-chain (TCR) associated protein kinase 70 209, 81 123, 55 
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Supplemental Figure 1.  mRNA expression profiling in rat adult ventricular myocytes (AVMs) and 
neonatal ventricular myocytes (NVMs).  Affymetrix microarrays were used for mRNA expression profiling 
of AVMs or NVMs (n=3, duplicate hybridisations) with GeneSpring for data analysis.  A, Heatmap for 
relative expression of all expressed mRNAs detected in AVMs and/or NVMs.  Data were normalised to the 
gene median and are individual values on a log2 scale.  Hierarchical clustering used a Euclidean similarity 
measure with Ward's linkage rule.  B-D, Expression data for cell cycle-dependent genes (B), genes required 
for DNA replication (C) and genes established to be regulated during postnatal cardiomyocyte 
development (D).  Results are mean raw fluorescence values for NVMs (yellow) and AVMs (cyan). 
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Supplemental Figure 2.  Comparison of neonatal cardiomyocytes and cardiac non-myocytes.  
Cells in the NVM cultures were immunostained with antibodies to troponin T to identify cardiomyocytes 
(green, A and D) and counterstained with phalloidin to identify all cardiac cells (red, B and E).  Images 
from A and D were overlaid onto B and E, respectively, in panels C and F.  Results are representative of 
multiple experiments.  G and H, qPCR analysis of Orc1-6 (G) and myocyte-specific gene expression 
(H, yellow bars) in NVMs and neonatal ventricular non-myocytes (NVNMs, red bars).  Results (relative 
to Gapdh and normalised to the mean of values in NVNMs) are means ± SEM (n=3).
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Supplemental Figure 3.  Protein expression of selected protein kinases in rat adult ventricular 
myocytes (AVMs) and neonatal ventricular myocytes (NVMs).  NVM and AVM extracts (20 µg and 
40 µg, respectively) were immunoblotted with antibodies to the indicated protein kinases.  A, Zak was 
detected in NVMs as the smaller isoform previously referred to as MLK7 (~52 kDa) rather than the longer 
isoform (~92 kDa).  B, Map4k4 was detected as multiple isoforms in NVMs.  C, Map3k8 and Tnni3k 
were more abundant in AVMs than NVMs.  D, BRaf, ERK1/2, Map4k4, MST1, MST3, PKCδ, Ripk2 and 
Zak were more highly expressed in NVMs than AVMs.  Each lane represents an independent 
cardiomyocyte preparation.
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Fuller et al. Supplemental Figure 4.
Supplemental Figure 4.  Quantitative immunoblotting of selected protein kinases in rat 
adult ventricular myocytes (AVMs) and neonatal ventricular myocytes (NVMs).  Proteins from 
individual cardiomyocyte preparations were immunoblotted for MKK1/2, Akt1/2/3, p38-MAPK, Ripk1 
and Pkn2 alongside GST fusion protein standards of known concentration.  
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Fuller et al. Supplemental Figure 5.
Supplemental Figure 5.  Protein expression of selected protein kinases in cardiomyocytes 
compared with whole hearts.  Proteins from individual cardiomyocyte or cardiac preparations were 
immunoblotted for MKK1/2, Akt1/2/3, ERK1/2, p38-MAPK, Ripk1 MST1, MST2, Pkn1 and Pkn2.  
